Human Life Code Secures Approx. 770 Million Yen in Funding for MSC Product Development

Human Life Code Reports Significant Funding Achievement

Human Life Code, chaired by Masamitsu Harada and located in Chuo-ku, Tokyo, has successfully raised approximately 770 million yen in funding by September 2025. This includes investments from existing shareholders as well as various business enterprises, venture capitalists, individual investors, and company management during the extension round planned for fiscal year 2024.

The raised funds are aimed at commencing a Phase III clinical trial targeting non-infectious pulmonary complications (NIPCs) following hematopoietic stem cell transplantation. Additionally, there are plans to establish a robust supply chain for UC-MSCs in Japan and the U.S. by collaborating with partner companies. This involves securing umbilical cord-derived materials and enhancing the production and supply processes for master cells and product cells.

About Human Life Code

Human Life Code focuses on manufacturing and developing cell products from domestically sourced and storable umbilical cord tissues. Their mission is to provide hope for patients suffering from diseases without established treatments. The ultimate vision is to extend health spans by preventing the exacerbation of diseases, thereby creating a society where everyone can lead enriching lives.

Over the years, Human Life Code has received numerous accolades, including the Grand Prize and Governor's Award at the 1st Tokyo Venture Company Championship in 2019. Furthermore, the company has been selected as a supported enterprise under the 'Deep Ecosystem' initiative by the Tokyo Startup Ecosystem Consortium and was awarded the Minister of Health, Labour and Welfare Prize at the 5th Japan Open Innovation Awards in 2023, hosted by the Cabinet Office.

Continuing the recognition for their innovative approach, Human Life Code was also selected for the J-Startup program by the Ministry of Economy, Trade, and Industry and received the Startup Division Grand Prize at the 2024 Courageous Management Awards hosted by the Tokyo Chamber of Commerce and Industry. These achievements underline the company’s commitment to pioneering advancements in regenerative medicine.

As the medical landscape evolves, Human Life Code endeavors to leverage their funding to drive forward the development of their UC-MSCs, focusing on the critical areas of stem cell therapy, which could potentially transform patient care and treatment outcomes globally. With strong backing and a clear vision, the company is poised to make significant contributions to the field of regenerative medicine and offer new hope to individuals facing challenging health conditions.